PD-L1 (Atezolizumab) Recombinant Human Monoclonal Antibody (Atezolizumab), Functional Grade, Leinco Technologies™

Human Recombinant Monoclonal Antibody

Supplier:  Leinco Technologies Inc LT1750100MG

Catalog No. 50-254-4124

Description

Specificity: Atezolizumab (RG7446; INN or code name MPDL3280A) activity is directed against PD-L1 (CD274) and B7.1 (CD80). Endotoxin Level: <1.0 EU/mg as determined by the LAL method. Purity: ≥95% monomer by analytical SEC. Preparation: Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage: Functional grade biosimilar antibodies may be stored sterile as received at 2-8C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80C. Avoid Repeated Freeze Thaw Cycles.

PD-L1 (Atezolizumab) Recombinant Monoclonal antibody specifically detects PD-L1 (Atezolizumab) in Human samples. It is validated for Flow Cytometry, Western Blot

Specifications

• Antigen: PD-L1 (Atezolizumab)
• Classification: Recombinant Monoclonal
• Concentration: ≥5.0 mg/mL
• Formulation: PBS with no preservative; pH 7.2-7.4
• Host Species: Human
• Purification Method: Protein A/G
• Regulatory Status: RUO
• Target Species: Human
• Product Type: Antibody
• Isotype: IgG

• Applications: Flow Cytometry, Western Blot
• Clone: Atezolizumab
• Conjugate: Functional Grade
• Gene Alias: MPDL3280A; RG7446; Tecentriq
• Immunogen: Recombinant extracellular domain-Fc fusion of human PD-L1R
• Quantity: 100 mg
• Primary or Secondary: Primary
• Content And Storage: 4°C short term, -80°C long term
• Form: Liquid